Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles

Chih-Hsiang Leng, Ph.D.

Associate Investigator
Vaccine Research and Development Center


  • Ph.D., Life Science, National Defense Medical Center, Taiwan, 1998
  • M.S., Life Science, National Tsing-Hua University, Taiwan, 1990
  • B.S., Physics, National Tsing-Hua University, Taiwan, 1988


  • Assistant Investigator, Vaccine research and development center, National Health Research Institutes, Taiwan (2004-present)
  • Core Manager (Hi-tech technologist), High throughput protein production core, Inst. of Biological Chemistry, Academia Sinica, Taiwan (2002-2003)
  • Platform Manager, Scientist, Department of research and development, United Biomedical Inc. Asia (2000-2002)
  • Associate Scientist, Department of research and development, United Biomedical Inc. Asia (1999-2000)
  • Postdoctoral Fellow, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (1998-1999)


    Dr. Lengs major interest is to develop the subunit vaccine for the infectious diseases. Currently he is working on the development of subunit vaccines for influenza virus and respiratory syncytial virus (RSV) projects. Also, he is trying to develop a platform technology for self-immunomodulating subunit vaccine. His laboratory established the E. coli and baculovirus expression system as well as downstream processes in NHRI vaccine R& D center.


    Dr. Leng has established a high through-put recombinant protein screening system in Academia Sinica. The platform technologies can screen 6 different fusion patterns to select which pattern can improve the expression level and the solubility of the target protein. He has got a SBIR grant from Ministry of economic affairs and performed a pilot production of a recombinant biologics.


    1.Lien SP, Shih YP, Chen HW, Tsai JP , Leng CH, Lin MH, Lin LH, Liu SY, Chou AH, Chang YW, Chen YM, Chong P, Liu SJ. Identification of Synthetic Vaccine Candidates against SARS CoV Infection. Biochem. Biophy. Res. Commun. 358: 716-21, 2007.

    2.Liu SJ, Leng CH, Lien SP, Chi HY, Huang CY, Lin CL, Lian WC, Chen CJ, Hsieh SL, Chong P. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine. 24: 31003108, 2006.

    3.Tsao YP, Lin JY, Jan JT, Leng CH, Chu CC, Yang YC, Chen SL. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commu.344: 6371, 2006.

    4.Chang YC, Lo YH, Lee MH, Leng CH, Chang CS, Wang TF. Molecular Visualization of Yeast Dmc1-ssDNA Nucleoprotein Filament by Atomic Force Microscopy Using Carbon Nanotube Tips. Biochemistry. 44: 6052-6058, 2005.

    5.Leng CH, Lee MH, Chang YC, Chou CC, Chen YK, Hsu FF, Chang CS, Wang HJ, Wang TF. Self-polymerization of archaeal RadA protein into long and fine helical filament. Biochem Biophys Res Commu. 323:845-851, 2004.

    6.Leng CH, Chen YK, Olivares H, Lee MH, Chang YC, Kung WM, Ti SC, Lo YH, Wang HJ, Chang CS, Bishop DK, Hsueh YP, Wang TF. Heterodimeric Complexes of Meiosis-Specific Hop2p and Mnd1p facilitate Homolog Juxtaposition and DNA Recombination. Proc Natl Acad Sci USA. 101:10572-10577, 2004.

    7.Leng CH, Brodsky JL, Wang C. Isolation and characterization of a DnaJ-like protein in rats: The C-terminal 10 Kda domain of hsc 70 is not essential for stimulating the ATP-hydrolytic activity of hsc 70 by a Dna-like protein. Protein Sci. 7:1186-1194, 1998.


  • US PTO patent application No. 60942703 "DENGUE VIRUS PEPTIDE VACCINE AND METHODS OF PREPARING AND USING THE SAME"; Submitted July, 2006.
  • US PTO patent application No. 61012263 "High level Expression of recombinant lipoprotien in E. coli system"; Submitted December, 2007.
  • US PTO patent application No. 61013206 "High Novel Lipidation Sequence for Lipoprotein Expresssion in E. coli system "; Submitted December, 2007.